DK1169021T3 - Sammensætninger og fremgangsmåder til behandling af lymfom - Google Patents

Sammensætninger og fremgangsmåder til behandling af lymfom

Info

Publication number
DK1169021T3
DK1169021T3 DK00920004T DK00920004T DK1169021T3 DK 1169021 T3 DK1169021 T3 DK 1169021T3 DK 00920004 T DK00920004 T DK 00920004T DK 00920004 T DK00920004 T DK 00920004T DK 1169021 T3 DK1169021 T3 DK 1169021T3
Authority
DK
Denmark
Prior art keywords
mol
compositions
methods
cholesterol
lymphoma
Prior art date
Application number
DK00920004T
Other languages
Danish (da)
English (en)
Inventor
D Lawrence Mayer
Murray S Webb
Clive T R Burge
Andreas H Sarris
Patricia M Logan
Fernando Cabanillas
James H Goldie
Original Assignee
Hana Biosciences Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hana Biosciences Inc, Univ Texas filed Critical Hana Biosciences Inc
Application granted granted Critical
Publication of DK1169021T3 publication Critical patent/DK1169021T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00920004T 1999-04-01 2000-03-31 Sammensætninger og fremgangsmåder til behandling af lymfom DK1169021T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (1)

Publication Number Publication Date
DK1169021T3 true DK1169021T3 (da) 2010-01-11

Family

ID=26825635

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10011105.3T DK2266537T3 (en) 1999-04-01 2000-03-31 Compositions for treating cancer
DK00920004T DK1169021T3 (da) 1999-04-01 2000-03-31 Sammensætninger og fremgangsmåder til behandling af lymfom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10011105.3T DK2266537T3 (en) 1999-04-01 2000-03-31 Compositions for treating cancer

Country Status (14)

Country Link
EP (3) EP1169021B1 (ja)
JP (3) JP2002541088A (ja)
AT (1) ATE442839T1 (ja)
AU (1) AU777572B2 (ja)
BR (1) BRPI0009448B8 (ja)
CA (1) CA2366787C (ja)
CY (1) CY1109641T1 (ja)
DE (1) DE60042968D1 (ja)
DK (2) DK2266537T3 (ja)
ES (2) ES2333400T3 (ja)
HK (1) HK1152246A1 (ja)
IL (4) IL145720A0 (ja)
PT (1) PT1169021E (ja)
WO (1) WO2000059473A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
BRPI0009448B8 (pt) * 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1389089B1 (en) * 2001-03-27 2009-08-26 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
DE60331537D1 (de) * 2002-05-17 2010-04-15 Celgene Corp Kombinationen zur behandlung von multiplem myelom
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
CA2568526C (en) * 2004-07-09 2015-11-03 Schering Aktiengesellschaft Combination therapy with radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
AU2005272946B2 (en) * 2004-08-10 2012-01-12 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
CA2741265A1 (en) * 2008-10-24 2010-04-29 Gloucester Pharmaceuticals Cancer therapy
US9801874B2 (en) * 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
WO2014116866A1 (en) * 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BRPI0009448B8 (pt) * 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero

Also Published As

Publication number Publication date
DE60042968D1 (de) 2009-10-29
JP2015071631A (ja) 2015-04-16
EP2266537B1 (en) 2014-09-03
WO2000059473A1 (en) 2000-10-12
CA2366787A1 (en) 2000-10-12
EP2266537A3 (en) 2012-02-22
BRPI0009448B1 (pt) 2018-09-11
AU777572B2 (en) 2004-10-21
ES2333400T3 (es) 2010-02-22
IL212390A (en) 2014-08-31
IL145720A (en) 2011-05-31
JP2002541088A (ja) 2002-12-03
BR0009448A (pt) 2002-01-08
HK1152246A1 (en) 2012-02-24
EP1985285A3 (en) 2009-08-12
CY1109641T1 (el) 2014-08-13
ES2524141T3 (es) 2014-12-04
EP1985285A2 (en) 2008-10-29
EP1169021A1 (en) 2002-01-09
BRPI0009448B8 (pt) 2021-05-25
JP2012158602A (ja) 2012-08-23
IL145720A0 (en) 2002-07-25
IL212389A (en) 2015-07-30
ATE442839T1 (de) 2009-10-15
DK2266537T3 (en) 2014-12-15
JP5981214B2 (ja) 2016-08-31
PT1169021E (pt) 2009-11-18
CA2366787C (en) 2013-03-12
EP2266537A2 (en) 2010-12-29
IL212390A0 (en) 2011-06-30
AU4060600A (en) 2000-10-23
IL212389A0 (en) 2011-06-30
EP1169021B1 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
DK1169021T3 (da) Sammensætninger og fremgangsmåder til behandling af lymfom
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
SE8502573D0 (sv) Fluorescent lanthanide chelates useful as labels of physiologically active materials
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
HN2000000109A (es) Trifluorbutenos nematicidas
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
HK1085675A1 (en) Anticancer compounds
GB0011203D0 (en) Chemical compounds
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
SE0104248D0 (sv) Method of treatment
PL338339A1 (en) Novel derivatives of tetrazole
MXPA03011306A (es) Metodos para la preparacion y uso de 1a,24 (s) - hidroxivitamina d2.
GB2358395B (en) Tetrahydrofuran-adducted group 11 ß-diketonate complexes as source reagents for chemical vapor depostion
CA2052640A1 (en) Method for destroying cyst of noxious plankton
FI981810A0 (fi) Menetelmä alkuainepitoisuuksien määrittämiseksi
TR200001819T2 (tr) COPD tedavi yöntemi.
DE69724472D1 (de) Selenophen-antitumormittel
DK0909182T3 (da) Fremgangsmåde til fremstilling af chloriner og bakteriochloriner indeholdende polyether
TR200002755T2 (tr) Aracı hazırlamak için süreç.
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
EP0732753A3 (en) Method for determining nitrogen concentration in a semiconductor compound
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
UA70975C2 (uk) Похідні 1,4-діарил-2-фтор-1-бутен-3-олу, спосіб їх одержання та способи одержання похідних 1,4-діарил-2-фтор-1,3-бутадієну і 1,4-діарил-2-фтор-2-бутену
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren